Business & Finance
Business and Finance
Business and Finance
Tue, March 17, 2009Mon, March 16, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Sun, March 1, 2009Sat, February 28, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Chemaphor Inc.: Chemaphor Announces Launch of Specialty Chemicals Business
Published on Monday, March 2nd 2009 at 6:50 GMT, Last Modified on 2009-03-02 06:51:41 by Market Wire
OTTAWA, CANADA--(Marketwire - March 2, 2009) - Chemaphor Inc. (TSX VENTURE:CFR), a biotechnology research and development company today announced the launch of its Specialty Chemicals business. Chemaphor has core expertise in organic chemistry and as a secondary activity, specializes in the synthesis of research chemicals labeled with stable isotopes. The use of carefully selected and tested synthetic techniques yields deuterated compounds of high purity (99%) and high levels of enrichment (99%). Deuterated products in stock include vitamin D and its hydroxy metabolites, cholesterol and its hydroxy metabolite, and vitamin E (alpha-tocopherol). Custom chemical synthesis is also available to help customers meet their research needs.
Isotopically labeled chemicals are extremely valuable research tools with many applications. They can be used as internal standards for analytical chemistry, and they are especially useful in the study of the metabolism of their non-labeled counterparts. Of particular interest in this regard are the recent reports of the apparent benefit of vitamin D in helping protect against cancer and cardiovascular disease, which is stimulating new research into the role of vitamin D. Chemaphor is one of very few companies in the world that has produced a comprehensive selection of high purity, highly enriched deuterated vitamin D forms that afford researchers important tools for probing the biochemical mechanisms of vitamin D action in the body.
About Chemaphor
Chemaphor Inc. ([ www.chemaphor.com ]) uses its core expertise in organic chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. The Company's focus is on two proprietary products, a non pharmaceutical product OxBC and a lead cancer drug compound OCL-1. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.
Forward-looking statements
This news release contains forward-looking information. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Chemaphor Inc. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Chemaphor Inc. does not assume any obligation to update or revise them to reflect new events or circumstances.
The TSX-Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
